Site-specific delivery of chemotherapeutics specifically to neoplastic hepatocytes without affecting normal hepatocytes should be a focus for potential therapeutic management of hepatocellular carcinoma (HCC). The aptamer TLS 9a with phosphorothioate backbone modifications (L5) has not been explored so far for preferential delivery of therapeutics in neoplastic hepatocytes to induce a... https://www.roneverhart.com/HP-Pavilion-15-eg1053cl-15-6-FHD-Touch-Intel-Core-i5-1235U-3-30-GHz-Intel-Iris-Xe-Graphics-12-GB-DDR4-RAM-512-GB-SSD-/